Neurocrine Biosciences Inc. / Soleno Therapeutics, Inc.

Hyperphagia in Prader-Willi syndrome (PWS)

10K US cases/yr · $190M VYKAT XR FY2025 net product revenue (Soleno 10-K)

Disease Overview

Prader-Willi syndrome (PWS) is a rare, complex genetic neurodevelopmental disorder caused by loss of expression of paternally inherited imprinted genes on chromosome 15q11-q13 - via paternal deletion (~60%), maternal uniparental disomy (~35%), or imprinting defect (~5%). Per the National Organization for Rare Disorders (NORD) and NIH Genetic and Rare Diseases Information Center (GARD), U.S. prevalence is estimated at 1 in 15,000-30,000 live births, equating to roughly 10,000-20,000 diagnosed U.S. patients. The clinical course is biphasic: infantile hypotonia and feeding difficulty transition in early childhood (typically age 2-8) to insatiable hunger (hyperphagia), food-seeking behavior, and hyperphagia-driven morbid obesity that without intervention becomes life-threatening through type 2 diabetes, cardiovascular disease, sleep apnea, and food-related accidents (including gastric rupture). Additional features include hypothalamic dysfunction (growth hormone deficiency, hypogonadism), intellectual disability (typically mild-moderate), behavioral rigidity, skin-picking, and psychiatric comorbidities. Hyperphagia is considered the most distressing symptom by caregivers and the leading cause of premature mortality. Until 2025, no FDA-approved therapy addressed hyperphagia; management relied on 24/7 food security measures (locked cabinets, supervised meals), growth hormone replacement (Genotropin etc. for growth-related indications), and behavioral interventions. Soleno's VYKAT XR (diazoxide choline extended-release) received FDA approval March 2025 as the first treatment for PWS hyperphagia.

Competitive Landscape

The PWS hyperphagia market is effectively a monopoly for Soleno's VYKAT XR, with several differentiated mechanisms in development. ATP-sensitive potassium channel activators: VYKAT XR (diazoxide choline extended-release, Soleno - the Neurocrine target) is first and only FDA-approved therapy for PWS hyperphagia (March 2025) based on the DESTINY-PWS Phase 3 randomized-withdrawal trial showing statistically significant reduction in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score; generated $190M 2025 net product revenue. Oxytocin-pathway agents: Levo Therapeutics' LV-101 (intranasal carbetocin) failed Phase 3 CARE-PWS endpoint in 2022 and Acadia Pharmaceuticals' intranasal carbetocin (ACP-101) was discontinued in 2023 after Phase 3 failure. MC4R agonists: Rhythm Pharmaceuticals' Imcivree (setmelanotide) is approved for other genetic obesity syndromes (POMC/LEPR/PCSK1/BBS) but did not receive PWS approval after a missed Phase 3 endpoint; Rhythm has not pursued PWS further. GLP-1/GIP and emerging hypothalamic agents: Saniona's tesofensine (triple monoamine reuptake inhibitor) is in Phase 2; Harmony Biosciences' pitolisant (Wakix) is in Phase 3 for PWS-associated EDS (a different symptom domain, not hyperphagia). Growth hormone: Genotropin (somatropin, Pfizer) is standard-of-care for PWS growth indications but does not address hyperphagia. Neurocrine's acquisition thesis rests on VYKAT XR's first-in-class durable monopoly through patent exclusivity and the scarcity of late-stage hyperphagia mechanisms.